Clara B. Calderon-Garcia

Sevilla, AN, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Journal: Blood advances
Published: August 05, 2025

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.

Journal: Blood advances
Published: August 05, 2025

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Journal: Blood advances
Published: February 25, 2025

Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions.

Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions.

Journal: British journal of cancer
Published: July 04, 2023

Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.

Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 21, 2023

Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.

Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.

Journal: Frontiers in immunology
Published: January 27, 2023

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.

Journal: Scientific reports
Published: December 15, 2021

FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2'-deoxycytidine and 5-hydroxymethyl-2'-deoxyuridine.

FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2'-deoxycytidine and 5-hydroxymethyl-2'-deoxyuridine.

Journal: Cell death & disease
Published: October 25, 2021

Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery.

Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery.

Journal: Pharmaceutics
Published: July 20, 2021

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.

Journal: Frontiers in pediatrics
Published: October 06, 2020

Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material.

Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material.

Journal: Pharmaceutics
Published: April 09, 2020

Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.

Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.

Journal: Bone marrow transplantation
Published: January 09, 2019
Showing 1-12 of 16

Last Updated: 09/26/2026